论文部分内容阅读
目的:探讨氨曲南联合恩替卡韦对乙肝肝硬化原发性腹膜炎患者血清甲状腺激素水平及临床疗效的影响。方法:选择于我院就诊的乙肝肝硬化原发性腹膜炎患者60例,根据电脑生成的随机数字表将所有患者随机分为实验组和对照组,每组各30例,对照组患者给予氨曲南进行治疗,实验组患者在对照组的基础上联合应用恩替卡韦进行治疗。比较治疗前后两组患者血清甲状腺激素、中性粒细胞比例、血白细胞及腹水细胞水平,并对治疗前后两组患者的体重、腹围及24 h尿量进行记录。结果:与治疗前相比,两组患者血清TSH水平、体重、腹围均降低,FT3、FT4、T3、T4水平及24 h尿量升高(P<0.05);与对照组相比,实验组患者血清TSH水平、体重、腹围较低,FT3、FT4、T3、T4水平及24h尿量较高(P<0.05);临床总有效率较高(P<0.05)。结论:氨曲南联合恩替卡韦对乙肝肝硬化原发性腹膜炎具有较好的临床疗效,推测其机制与改善甲状腺激素水平,降低炎症反应有关。
Objective: To investigate the effect of aztreonam combined with entecavir on serum thyroid hormone level and clinical efficacy in patients with primary liver cirrhosis and chronic peritonitis. Methods: Sixty patients with primary peritonitis of hepatitis B cirrhosis were selected for treatment in our hospital. All patients were randomly divided into experimental group and control group according to random number table generated by computer. Each group was given 30 cases of amikacin South treatment, the experimental group of patients in the control group based on the combination of entecavir for treatment. Serum levels of thyroid hormones, neutrophils, blood leucocytes and ascites cells were compared between the two groups before and after treatment. The body weight, abdominal circumference and 24-hour urine output of the two groups before and after treatment were recorded. Results: Compared with those before treatment, serum TSH level, body weight and abdominal circumference were decreased, FT3, FT4, T3, T4 levels and 24 h urine output were increased in both groups (P <0.05) Serum TSH level, body weight, abdominal circumference were lower, FT3, FT4, T3, T4 levels and 24h urinary volume were higher (P <0.05). The total clinical effective rate was higher (P <0.05). Conclusion: Aztreonam combined with entecavir has a good clinical effect on primary peritonitis of hepatitis B cirrhosis. It is speculated that its mechanism is related to the improvement of thyroid hormone level and the reduction of inflammatory reaction.